CoChat

Miglitol combined with metformin improves glycaemic control in type 2 diabetes

Open access
Van Gaal, L., Maislos, M., Schernthaner, G., Rybka, J., Segal, P. · 2001 · Diabetes, Obesity and Metabolism
Cited by 47

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

SUMMARY Aim To investigate the efficacy and safety of miglitol vs. placebo in type 2 diabetic outpatients insufficiently controlled (HbA 1c between 7.5 and 10.5%) with diet and metformin. Methods Patients treated with diet and metformin (1500–2250 mg/day) were randomized to receive additional treatment with either miglitol or placebo for 32 weeks. The dosages were force‐titrated: 4 weeks at 25 mg miglitol t.i.d., 12 weeks at 50 mg miglitol t.i.d., and 16 weeks at 100 mg miglitol t.i.d. or matching placebo. If the highest dosage could not be tolerated, patients could be down‐titrated to 50 mg t.i.d. The primary efficacy criterion was the change in glycated haemoglobin (HbA 1c ). Secondary efficacy parameters included fasting and 1 h postprandial blood glucose, serum insulin, and fasting and 1 h postprandial triglyceride levels. Safety and tolerability were evaluated by the incidence of adverse events and changes in vital signs or routine biochemical and haematological parameters. Results One hundred and fifty‐two patients were valid for the intent‐to‐treat (ITT) analysis. There was a significant decrease in HbA 1c on adding miglitol to metformin compared to adding placebo (miglitol treatment effect, − 0.21%; placebo treatment effect, + 0.22%; p = 0.011). Postprandial blood glucose declined in both the miglitol/metformin and placebo/metformin groups with a statistically significant difference in favour of miglitol/metformin (end of treatment adjusted means 13.8 mmol/l for miglitol vs. 15.8 mmol/l for placebo, p = 0.0007). Adverse events (AEs) were reported by only 8% more patients in the miglitol/metformin group than placebo/metformin. No cases of hypoglycaemia were reported. Conclusions Miglitol can safely and effectively be added to diet and metformin in patients whose type 2 diabetes is insufficiently controlled, and improves glycaemic control by significantly reducing HbA 1c and postprandial blood glucose levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1463-1326.2001.00141.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 47

Metadata

Authors
Van Gaal, L., Maislos, M., Schernthaner, G., Rybka, J., & Segal, P.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2001-10
Volume
3
Issue
5
Pages
326-331
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2017738196
Cited by
47
References
2
FWCI
1.87
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Miglitol combined with metformin improves glycaemic control in type 2 diabetes. https://app.cochat.ai/papers/10.1046/j.1463-1326.2001.00141.x
The paper
Van Gaal, L., Maislos, M., Schernthaner, G., Rybka, J., & Segal, P. (2001). Miglitol combined with metformin improves glycaemic control in type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1046/j.1463-1326.2001.00141.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.